Lu AA24493: Phase I started

H. Lundbeck began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate 0.5, 5 and 50 µg/kg of IV Lu AA24493 in 24 patients. The company licensed worldwide rights to Lu AA24493...